Fusion Antibodies Plc · LSE:FAB
Fusion Antibodies — Investor Presentation (December 2005)
22 slides from Fusion Antibodies's investor presentation, December 2005
Slide 1: Fusion Antibodies: from genes to proteins to antibodies
fusion antibodies from genes to proteins to antibodies
Slide 2: Introduction
Introduction • Why is recombinant technology superior to synthetic peptides? • Fusion Antibodies’ award winning proprietary platform technology to ensure the rapid production of high quality antibodies to clients. • Examples of projects performed by Fusion • Other services Fusion Antibodies provides
Slide 3: Recombinant Protein Synthesis
Recombinant Protein Synthesis • Maintains conformational folding which is crucial for proper epitope presentation. • Linear and conformational epitopes are displayed using protein antigen as opposed to linear only with peptide antigen. Protein Peptide
Slide 4: From your gene sequence to protein to purified antibody
Gene Protein Antibody Bridging the gap between genomics and antibody production From your gene sequence to protein to purified antibody.
Slide 5: The platform
The platform Fragments Protein Over-express in cloned with Modelling E. coli fusion tags High-throughput Platform polyclonal production Scale-up low pressure Quality control monoclonal purification & Expression production
Slide 6: Expression Optimisation
Expression Optimisation • An initial • Optimised purification purification
Slide 7: Protein Synthesis
Protein Synthesis To date – made over 170 recombinant proteins – Viral targets – Cancer targets • Hepatitis B • Vaccinia • Solid tumour • SARS • Leukaemia • HSV1,2 – Receptors • HTLV IIB • Ig-type receptors – Bacterial targets – Enzymes • Tuberculosis • Proteases • Burkholderia cepacea • Yersinia pe
Slide 8: Monoclonal antibody production
harvest B-cells, some making antibodies to the antigen (red) Infuse antigen mix myeloma cells with B-cells Antigen- mouse myeloma cell line test for monoclonal culture hybridoma antibodies using cells individually ELISA only B-cells that fuse with myeloma cells can replicate, some will produce an
Slide 9: In-house projects
In-house projects Synthetic gene synthesis (SGS) of extracellular fragments of a 7-membrane pass receptor Extracellular Extracellular Extracellular Extracellular a b cBeta2-Adrenergic ORF d Receptore f g 1242 bp ADBR2 extracellular 213 bp
Slide 10: Antibody Production Markers
Antibody Production Markers Siglec 3 Siglec 5 Siglec 6 Siglec 7.1 Siglec 7.2 Siglec 9 Siglec 10 Siglec 11 • Polyclonal – Rabbits immunised kDa with purified Siglec 7.1 98 – 4 boosts given 64 – Sera tested for 50 Siglec7 antibodies 36 – Titre = 1:1000 – 95ml sera produced 22 – Affinity Purified 16
Slide 11: Applications
Applications FACS analysis Western Blot PBMC lysates recombinant Siglec-7 38% +ve Key U937 cells –ve control U937 cells anti-Siglec-7
Slide 12: Vaccinia protein
Vaccinia protein 1 100 VP (1) ------------MKVESVTFLTLLGIGCVLSCCTIPSRPINMKFKNSVET-------------------------------------------------- C4b-BP (1) ---------------MFFWCACCLMVAWRVSASDAEHCPELPPVDNSIFV-------------------------------------------------- CR1 (1) -----------------MSLLAVVVLLALPVAWGQCNAPEWLPFARPTN
Slide 13: Vaccinia protein
Vaccinia protein Purified Vaccinia protein Fragments of the Vaccinia protein 15kDa Vaccinia antigen 10g kDa 34 17 16 7 Rabbit -Vaccinia Protein
Slide 14: Protein Modelling
Fus receptor 2 Protein Modelling Transporter Receptor Fus 2 Fus receptor 1
Slide 15: Transporter Receptor
Transporter Receptor Iso Ctrl Pos Ctrl MAb 1 MAb 3 MAb 4 MAb 2 Immuno Staining with MAb 2
Slide 16: Mammalian Expression
Mammalian Expression D-gag P MCS LTR Gene of Interest pRetMEx Ampr 7406 bp IRES eGFP LTR
Slide 17: Mutagenesis
Mutagenesis Human Janus kinase 3 (JAK3)
Slide 18: Other Services
Other Services • Antibody fragmentation – From hybridoma cell lines (scFv/FAb) • Monoclonal antibody sequencing – From hybridoma cell lines • Mammalian expression – Transient and stable
Slide 19: Examples of Orders and Collaborations
Examples of Orders and Collaborations Genomic Institute of Singapore
Slide 20: Testimonials
Testimonials • “the SOCS-3 antibody works good! I am very grateful!” – Maike Heffner: National Cancer Institute, Frederick, Maryland • “this is the best Syk antibody on the market” – Dan McVicar: NIH, Bethesda, Maryland • “we are … extremely happy with the protein that you provided. We will be using
Slide 21: Summary
Summary Why Use Fusion Antibodies • genes to proteins to antibodies • Recombinant proteins as superior antigens • Antibodies recognise native proteins – Receptors, intracellular proteins, microbial proteins • Rapid turnaround • Experts in protein expression and proteomics • Offer a complete range of
Slide 22: info@fusionantibodies.com
info@fusionantibodies.com
Fusion Antibodies — Investor Presentation (December 2005) on 6ix